title: [Targeted radionuclide therapy for castration-resistant prostate cancer].
abstract: Although patients with castration-resistant prostate cancer frequently have metastases to the bone, they have a relatively favorable prognosis. Therefore, it is important to keep or improve the level of patient's quality of life. The use of strontium-89 for the management of the pain from bone metastasis was approved in 2007 in Japan. A new bone-targeting radiopharmaceuticals using radium-223 is also promising, because a randomized trial showed an overall survival advantage of radium-223 in prostate patients with bone metastases. In this review, we summarize the role of targeted radionuclide therapy for castration-resistant prostate cancer, focusing on strontium-89 and radium-223.
authors.forename: Katsumasa
authors.initials: K
authors.lastname: Nakamura
authors.forename: Saiji
authors.initials: S
authors.lastname: Ohga
authors.forename: Tomonari
authors.initials: T
authors.lastname: Sasaki
authors.forename: Shingo
authors.initials: S
authors.lastname: Baba
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Honda
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000532:radiotherapy* / Q000556:secondary; D006801:Humans; D008297:Male; D064129:Prostatic Neoplasms, Castration-Resistant / Q000473:pathology / Q000532:radiotherapy*; D011868:Radioisotopes / Q000627:therapeutic use; D019275:Radiopharmaceuticals / Q000627:therapeutic use*; D011883:Radium / Q000627:therapeutic use; D013326:Strontium Radioisotopes / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D011868:Radioisotopes; D019275:Radiopharmaceuticals; D013326:Strontium Radioisotopes; C581106:radium Ra 223 dichloride; D011883:Radium